NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Celosia Therapeutics

Celosia Therapeutics

Private
SydneyHealthcare & Life Scienceshttps://celosiatx.com/

Last Round

Series A

Nov 28, 2024

Total Funding Raised

$12.92M

Company Overview

Celosia Therapeutics is a biotechnology company that develops precision gene therapies for neurodegenerative diseases, including ALS, FTD, and Alzheimer's disease.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

gene therapyAAV-based gene therapyneurodegenerative diseaseALSAmyotrophic Lateral SclerosisFrontotemporal DementiaFTDprecision medicinebiotechdrug discoveryclinical stage biotechTDP-43genetic medicineclinical trialstherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Celosia Therapeutics Comps

Public and private peers based on sector, stage, and business model.

Celosia Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Celosia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ANov 28, 2024
SeedOct 31, 2022
View all Funding Rounds

Key People

Founding team and executive leadership

Lars Ittner

Chief Medical Officer, Co-Founder

Founding Team

Kathryn Sunn

Chief Executive Officer

Executive Team

Yazi Diana Ke

Chief Operating Officer

Executive Team

Celosia Therapeutics Investors

Notable investors and investment history

Celosia Therapeutics investors
InvestorRounds
UniSuper ManagementSeries A
UniseedSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 28, 2024

    $11M round led by Uniseed.

View all signals

Celosia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Celosia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Celosia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSydney
Employee Range5
Year Founded2022
Last FundingNov 28, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.